Browsing Tag
LAVA Therapeutics
2 posts
Why did XOMA give shareholders two more weeks on the LAVA Therapeutics deal – and what happens next?
XOMA (NASDAQ: XOMA) extends its tender offer for LAVA Therapeutics (NASDAQ: LVTX) to Oct 17. Explore shareholder impact, CVR value, and deal prospects.
LAVA Therapeutics gets FDA orphan drug status for LAVA-051 in CLL
LAVA Therapeutics has been granted orphan drug designation (ODD) in chronic lymphocytic leukemia (CLL) from the US Food…